Develops targeted oncology therapies, including an approved treatment for a rare form of lung cancer (Ibtrozi).
Develops targeted oncology therapies, including an approved treatment for a rare form of lung cancer (Ibtrozi).
Its marketed drug Ibtrozi, approved in the US in 2025, came through the 2024 purchase of AnHeart Therapeutics, and product revenue starts from that launch. Oncologists prescribe it for patients whose tumours carry a ROS1 gene change, and it uses cash and launch revenue to fund the rest of its pipeline.
Moat: none (IP / patents, regulatory licence). Newly approved targeted therapy for a genetically defined lung cancer subtype, in a competitive class.
Headquarters: New York City, US · Founded: 2018 · Employees: 298
Size Nuvation Bio (NUVB) is a United States Health Care company (Biotechnology) with a market value of $1.34B, the 2052nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.78 on 18 Nov 2026.
Performance Over six months the shares fell 16.2%, against -20.3% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue grew 654.2% over the last twelve months (peer median +13.0%); the operating margin is -61.2% (peer median -155.8%).
Valuation It trades at 5.7× enterprise value to sales against a peer median of 15.2× (6th cheapest of 19).
Short interest Short interest is 17.6% of the free float (30 Oct 2026).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $202M | $62.9M | $7.87M | $0 | $0 |
| Revenue growth | — | +699% | — | — | — |
| Gross profit | $171M | $51.9M | $112,000 | -$222,000 | -$484,000 |
| EBITDA | -$121M | -$211M | -$167M | -$99.6M | -$119M |
| Net income | -$136M | -$205M | -$568M | -$75.8M | -$104M |
| Free cash flow | -$108M | -$174M | -$131M | -$68.1M | -$96.5M |
| Capital expenditure | $1.98M | $8.35M | $162,000 | $69,000 | $370,000 |
| Total debt | $468M | $213M | $8.91M | $4.01M | $4.26M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Nuvation Bio NUVB | $1.34B | -16% | +654% | -61% | 5.7× | n/a |
| Roche RO.SW | $381B | +21% | -1% | 31% | 5.7× | 1.7% |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NUVB | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.8% | -15.3% | 5th lowest of 21 |
| 6-month return | -16.2% | -20.3% | 8th highest of 20 |
| Distance from 52-week high | -61.2% | -46.5% | 4th lowest of 21 |
| Revenue growth (TTM) | +654.2% | +13.0% | 2nd highest of 18 |
| Operating margin | -61.2% | -155.8% | 10th highest of 19 |
| EV / Sales | 5.7× | 15.2× | 6th cheapest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nuvation Bio NUVB | United States | $1.34B | -16% | +654% | -61% | 5.7× | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | 31.7× | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.32B | n/a | +238% | -1,196% | 164.8× | n/a | n/a |
| Novavax NVAX | United States | $1.31B | -14% | -61% | -17% | 2.4× | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.36B | -23% | +36% | -4% | 6.8× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | 21.3× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | 408.9× | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.30B | -27% | -13% | -2,998% | 170.1× | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | 50.1× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 7.9× | 0.5% | +25.6% |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a | n/a |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 4.9× | 39.4% | -2.5% |
| Hualan Biological Vaccine 301207.SZ | China | $1.25B | -29% | -28% | -7% | 9.0× | 33.2% | -13.1% |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | 2.3× | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.24B | -21% | +1% | 10% | 3.5× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | 205.0× | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 6.3× | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.22B | -14% | -9% | 0% | 2.2× | 6.6% | -7.0% |
| Mineralys Therapeutics MLYS | United States | $1.22B | -52% | n/a | n/a | n/a | n/a | n/a |